{
    "ticker": "FULC",
    "name": "Fulcrum Therapeutics, Inc.",
    "description": "Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare genetic diseases. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum aims to transform the lives of patients by targeting the underlying genetic causes of their conditions. The company utilizes its proprietary Gene Traffic Control platform to discover and develop small molecule therapies that modulate gene expression. Their lead product candidate, FTX-6058, is being evaluated for the treatment of sickle cell disease, a painful and debilitating condition that affects millions globally. By leveraging cutting-edge science and a patient-centric approach, Fulcrum is committed to addressing significant unmet medical needs within the rare disease community. The company\u2019s pipeline also includes therapies for other genetic disorders, showcasing its dedication to advancing the field of genetic medicine. Fulcrum Therapeutics strives to build partnerships with the scientific community and patient advocacy groups to further enhance its research and development efforts. As the company progresses through clinical trials, it remains focused on ensuring that its therapies are both effective and safe for patients, believing that breakthroughs in medicine can lead to better health outcomes and improved quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.fulcrumtx.com",
    "ceo": "Robert J. McCauley",
    "social_media": {
        "twitter": "https://twitter.com/FulcrumTX",
        "linkedin": "https://www.linkedin.com/company/fulcrum-therapeutics"
    },
    "investor_relations": "https://investors.fulcrumtx.com",
    "key_executives": [
        {
            "name": "Robert J. McCauley",
            "position": "CEO"
        },
        {
            "name": "Sharon H. Mates",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "FTX-6058"
            ]
        }
    ],
    "seo": {
        "meta_title": "Fulcrum Therapeutics, Inc. | Innovative Therapies for Rare Genetic Diseases",
        "meta_description": "Fulcrum Therapeutics focuses on developing therapies for rare genetic diseases, utilizing innovative science to transform patient lives. Learn more about our pipeline and mission.",
        "keywords": [
            "Fulcrum Therapeutics",
            "Biotechnology",
            "Rare Diseases",
            "Genetic Therapies",
            "Clinical Trials",
            "FTX-6058"
        ]
    },
    "faq": [
        {
            "question": "What does Fulcrum Therapeutics focus on?",
            "answer": "Fulcrum Therapeutics focuses on developing innovative therapies for rare genetic diseases."
        },
        {
            "question": "Where is Fulcrum Therapeutics headquartered?",
            "answer": "Fulcrum Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Fulcrum's lead product candidate?",
            "answer": "Fulcrum's lead product candidate is FTX-6058, which is being developed for sickle cell disease."
        },
        {
            "question": "When was Fulcrum Therapeutics founded?",
            "answer": "Fulcrum Therapeutics was founded in 2015."
        },
        {
            "question": "Who is the CEO of Fulcrum Therapeutics?",
            "answer": "Robert J. McCauley is the CEO of Fulcrum Therapeutics, Inc."
        }
    ],
    "competitors": [
        "SRPT",
        "PTCT",
        "RARE",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}